循环肿瘤DNA测序比较去势敏感与去势抵抗前列腺癌的基因组改变
该研究通过胚系和循环肿瘤DNA测序探索中国去势敏感前列腺癌与转移性去势抵抗前列腺癌患者的基因组图谱。研究对396例患者的396份血样和32份配对肿瘤组织进行50基因靶向测序,发现两组有害胚系变异频率相似,转移性去势抵抗前列腺癌中DNA损伤修复和雄激素受体通路基因变异频率更高,且CDK12和FOXA1变异频率高于SU2C-PCF队列。
要点
- 去势敏感与去势抵抗前列腺癌的有害胚系变异频率相似(8.9% vs 9.8%,p>0.05)。
- 转移性去势抵抗前列腺癌中DNA损伤修复通路基因变异频率高于新发转移性去势敏感前列腺癌(66.7% vs 41.5%,p=0.015)。
- 循环肿瘤DNA测序可指导转移性前列腺癌的临床治疗。
核心结论
- 去势敏感前列腺癌与转移性去势抵抗前列腺癌患者的有害胚系变异频率相似。
- 转移性去势抵抗前列腺癌中雄激素受体和DNA损伤修复通路基因存在基因组多样性。
- 循环肿瘤DNA测序可指导转移性前列腺癌的临床治疗。
研究设计与样本
- 采用杂交捕获基于下一代测序技术检测50个基因的胚系和体细胞变异。
- 成功测序396例患者的396份血样和32份配对肿瘤组织样本。
主要发现
- 去势敏感与转移性去势抵抗前列腺癌的有害胚系变异频率相似(8.9% vs 9.8%,p>0.05)。
- 转移性肿瘤组织与配对循环肿瘤DNA一致性高达90.9%。
- 循环肿瘤DNA阳性患者中,本转移性去势抵抗前列腺癌队列CDK12变异频率为27.2% vs SU2C-PCF队列6.4%(p<0.001)。
- FOXA1变异频率为36.8% vs SU2C-PCF队列15.3%(p<0.001)。
- 转移性去势抵抗前列腺癌中DNA损伤修复通路基因变异频率66.7% vs 新发转移性去势敏感前列腺癌41.5%(p=0.015);雄激素受体通路基因变异频率71.9% vs 48.8%(p=0.018)。
关键数值与推荐
- 有害胚系变异频率在去势敏感与转移性去势抵抗前列腺癌间差异无统计学意义(8.9% vs 9.8%,p>0.05)。
- 转移性肿瘤组织与循环肿瘤DNA的一致性为90.9%。
- CDK12变异频率在转移性去势抵抗前列腺癌队列为27.2%,SU2C-PCF队列为6.4%(p<0.001)。
- FOXA1变异频率在转移性去势抵抗前列腺癌队列为36.8%,SU2C-PCF队列为15.3%(p<0.001)。
- DNA损伤修复通路基因变异频率在转移性去势抵抗前列腺癌为66.7%,新发转移性去势敏感前列腺癌为41.5%(p=0.015);雄激素受体通路基因变异频率分别为71.9%和48.8%(p=0.018)。
临床怎么用
- 循环肿瘤DNA测序可用于指导转移性前列腺癌的临床治疗决策。
- 对于转移性去势抵抗前列腺癌患者,应关注CDK12、FOXA1及DNA损伤修复通路基因的变异情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To explore the genomic profiles of Chinese patients with castration sensitive prostate cancer and those with metastatic castration resistant prostate cancer via germline and circulating tumor DNA sequencing. MATERIALS AND METHODS: A hybridization capture based next-generation sequencing assay was used to identify germline and somatic alterations in 50 genes including androgen receptor pathway genes, DNA damage repair pathway genes, TP53 and RB1. RESULTS: We successfully sequenced DNA from 396 blood samples and 32 matched tumor tissue samples from 396 patients. We observed a similar frequency of deleterious germline alterations between patients with castration sensitive prostate cancer and metastatic castration resistant prostate cancer (8.9% vs 9.8%, p >0.05). There was a high consistency (90.9%) between metastatic tumor tissue and matched circulating tumor DNA. Among patients who were circulating tumor DNA positive we observed significantly higher alteration frequencies of CDK12 (27.2% vs 6.4%, p <0.001) and FOXA1 (36.8% vs 15.3%, p <0.001) in our metastatic castration resistant prostate cancer cohort compared with the SU2C-PCF (Stand Up to Cancer-Prostate Cancer Foundation) cohort. Alteration frequencies of DNA damage repair pathway genes (66.7% vs 41.5%, p=0.015) and androgen receptor pathway genes (71.9% vs 48.8%, p=0.018) in patients with metastatic castration resistant prostate cancer were higher than in patients with de novo metastatic castration sensitive prostate cancer. Androgen receptor alteration was selectively enriched in metastatic castration resistant prostate cancer. CONCLUSIONS: Through genomic profiling of prostate cancer across clinical states we identified a similar frequency of deleterious germline alterations between patients with castration sensitive prostate cancer and metastatic castration resistant prostate cancer. We explored the genomic diversity of androgen receptor and DNA damage repair pathway genes between patients with metastatic castration sensitive prostate cancer and metastatic castration resistant prostate cancer. Higher alteration frequencies of CDK12 and FOXA1 were observed in our metastatic castration resistant prostate cancer cohort than in the SU2C-PCF cohort. Our findings support the view that circulating tumor DNA sequencing could guide clinical treatment for metastatic prostate cancer.
引用
- Fan L, Fei X, Zhu Y, et al. Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing. J Urol. 2020. PMID: 32897803. doi:10.1097/JU.0000000000001363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。